The main inclusion criteria include but are not limited to the following: - Has Lp(a) ≥ 150 nmol/L - Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study

The main exclusion criteria include but are not limited to the following: - Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH - Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization - Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load) - Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection - Has a history of nephrotic syndrome - Has severe renal insufficiency - Has received certain therapies in the prohibited timeframe as specified in the protocol - Has active or chronic hepatobiliary or hepatic disease - Has poorly controlled Type 1 or Type 2 diabetes